ABSTRACT
Green propolis is a resin produced from Baccharis dracunculifolia, which has as its main compounds flavonoids, derivatives of cinnamic acids, such as artepillin C and baccarin. This resin has antibacterial, antifungal, anti-inflammatory, antioxidant, and anticancer activities. This review aimed to analyze pharmaceutical patents containing green propolis in various formulations. The search was conducted in the National Institute of Industrial Property (INPI), the Patent Search of Spain and Latin America (Latipat-Espacenet), the World Intellectual Property Organization (WIPO), and Google Patents, with a combination of the keywords green propolis, green propolis extract, pharmacology, and pharmaceutical product. Primary research identified 60 patents, from which 22 were selected after applying the inclusion criteria. The selected patents referred to products with pharmacological activities, from cancer treatment to food supplements and included innovations for improved controlled release of the green propolis compounds. Most of the documents concerned the preparation and/or formulation of the green propolis extract, followed by innovative extraction methods, treatment and systemic use, and finally by topical use and quality control techniques and procedures. Thus, the reviewed patents of green propolis provided valuable insights into the pharmaceutical applications of green propolis, showing its potential in diverse formulations and treatments.
ABSTRACT
Reactive oxygen species (ROS) have been shown to modulate neuronal synaptic transmission and may play a role on the autonomic control of the cardiovascular system. In this study we investigated the effects produced by hydrogen peroxide (H(2)O(2)) injected alone or combined with the anti-oxidant agent N-acetil-l-cysteine (NAC) or catalase into the fourth brain ventricle (4th V) on mean arterial pressure and heart rate of conscious rats. Moreover the involvement of the autonomic nervous system on the cardiovascular responses to H(2)O(2) into the 4th V was also investigated. Male Holtzman rats (280-320 g) with a stainless steel cannula implanted into the 4th V and polyethylene cannulas inserted into the femoral artery and vein were used. Injections of H(2)O(2) (0.5, 1.0 and 1.5 micromol/0.2 microL, n=6) into the 4th V produced transient (for 10 min) dose-dependent pressor responses. The 1.0 and 1.5 micromol doses of H(2)O(2) also produced a long lasting bradycardia (at least 24 h with the high dose of H(2)O(2)). Prior injection of N-acetyl-l-cysteine (250 nmol/1 microL/rat) into the 4th V blockade the pressor response and attenuated the bradycardic response to H(2)O(2) (1 micromol/0.5 microL/rat, n=7) into the 4th V. Intravenous (i.v.) atropine methyl bromide (1.0 mg/kg, n=11) abolished the bradycardia but did not affect the pressor response to H(2)O(2). Prazosin hydrochloride (1.0 mg/kg, n=6) i.v. abolished the pressor response but did not affect the bradycardia. The increase in the catalase activity (500 UEA/1 microL/rat injected into the 4th V) also abolished both, pressor and bradycardic responses to H(2)O(2). The results suggest that increased ROS availability into 4th V simultaneously activate sympathetic and parasympathetic outflow inducing pressor and bradycardic responses.
